PubMed · 2005 · 13 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyClinical PharmacologyImmunotherapyCancer ImmunotherapyDeath ReceptorsMonoclonal Antibody TherapyTargeted Cancer TherapyTargeted TherapyTherapeutic Monoclonal AntibodiesAnti-apoptotic AgentsApoptosis TargetingApoptosis-inducing FactorEvaluationMonoclonal Antibody TherapeuticsPhase Ii Clinical TrialsTumor Necrosis Factor Inhibitor TherapyTumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors
Human Genome Sciences and GlaxoSmithKline, under license from Cambridge Antibody Technology, are developing mapatumumab, the intravenously administered lead from a series of human monoclonal antibody tumor necrosis factor-related apoptosis-inducing ligand receptor 1 agonists, for the potential treatment of cancer. The therapy is currently undergoing phase II clinical trials. Takeda is developing mapatumumab in Japan.